Everolimus in Treating Cutaneous T-cell Lymphoma

NCT01637090 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Poor enrollment

Conditions

Cutaneous T-Cell Lymphoma

Interventions

DRUG: Everolimus

Sponsor

Adam Lerner

Collaborators

[object Object]